ISSN: 2161-0681

Journal de pathologie clinique et expérimentale

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Sherpa Roméo
  • Ouvrir la porte J
  • JournalSeek de génamique
  • JournalTOC
  • Annuaire des périodiques d'Ulrich
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

Analysis of SHIP2 Expression and its Correlation with VEGF and HER-2 Expression in Breast Cancer

Han H, Wang B, Zhao J, Xu G, Wang X and Cao F

Purpose: To investigate SHIP2 expression in breast cancer tissues, and its correlation with clinicopathological features and with the expressions of VEGF and HER-2 in cancer tissues.

Methods: Immunohistochemical staining for SHIP2, HER-2 and VEGF was performed on paraffin-embedded tissue specimens, including 80 specimens of breast cancer and 53 adjacent tissue samples. Two pathologists were invited to interpret the immunohistochemistry results using double-blind method. Expression profiles of SHIP2, HER-2 and VEGF were evaluated and scored according to percentage of positive cells and positive signal intensity. The correlation between SHIP2 and clinicopathological features was analyzed by chi-square test and fourfold table exact test. The correlation among SHIP2, HER-2 and VEGF expression were analyzed using Pearson contingency coefficient analysis for evaluating prognostic relevance to breast cancer.

Results: The positive expression rates of SHIP2, HER-2 and VEGF were significantly higher than that of adjacent normal tissues (p<0.05). SHIP2 expression was significantly increased, in the case of the four risk factors (the poor histological grade, the later stages, lymph node metastasis, and higher BMI) (p<0.05). Positive rate of both SHIP2 and VEGF protein expression indicated a significant correlation between the two proteins (r=0.30, p<0.05). In addition, in the HER-2 protein positive group, SHIP2 protein expression also showed a positive correlation (r=0.71, p<0.05) between these two proteins. Expression of all three proteins were highly related to tumor histopathologic grade, clinical terms, and lymphatic metastasis (p<0.05). Our data indicates that SHIP2 expression in tumor tissue is significantly correlated with HER-2 and VEGF expression.

Conclusion: Our study provides a proof of concept that SHIP2, correlated with HER-2 and VEGF, plays important roles in tumorigenesis, infiltration, and metastasis of breast cancer, and are highly associated with prognosis.